AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions and listings of claims in the application.

Claim 1 (Currently Amended): A human cancer-related gene LAPTM4B isolated polynucleotide sequence, comprising one of the following nucleotide sequences:

- 1) SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, or SEQ ID No: 6 in the sequence listings; and
- 2) Polynucleotide that encodes SEQ ID No: 4, SEQ ID No: 5, or SEQ ID No: 7 protein sequences in the sequence listings; and
- 3) DNA sequences having above 90% homology to the DNA sequences defined by SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, or SEQ ID No: 6 in the sequence listings, and capable of encoding proteins with the same or similar functions.

Claim 2 (Currently Amended): The human cancer-related <u>isolated polynucleotide</u>

<u>sequence gene</u> according to claim 1, wherein the said <u>isolated polynucleotide sequence gene</u> is

SEQ ID No: 1 in the sequence listings.

Claim 3 (Currently Amended): The human cancer-related <u>isolated polynucleotide</u>

<u>sequence gene</u> according to claim 2 1, wherein the said <u>isolated polynucleotide sequence</u> is

SEQ ID No: 2 in the sequence listings.

Claim 4 (Currently Amended): The human cancer-related <u>isolated polynucleotide</u> sequence gene according to claim 2 1, wherein the said <u>isolated polynucleotide</u> sequence gene is SEQ ID No: 3 in the sequence listings.

Claim 5 (Currently Amended): The human cancer-related <u>isolated polynucleotide</u> sequence gene according to claim 2 1, wherein the said <u>isolated polynucleotide</u> sequence gene is SEQ ID No: 6 in the sequence listings.

Claim 6 (Currently Amended): The human cancer-related <u>isolated polynucleotide</u> sequence gene according to claim 1 or 2 or 3 or 4 or 5, wherein the said <u>human</u> cancers are selected from liver cancer, <u>lung cancer</u>, stomach cancer, colon cancer, and breast cancer and some epithelium sourced cancers.

Claim 7 (Withdrawn): The human cancer-related proteins, comprising (1) amino acid sequence 4 and/or sequence 5 and/or sequence 7; or (2) the derived protein comprising amino acid sequence 4 and/or sequence 5 and/or sequence 7 with one or several amino acid residues being replaced, deleted, or added, but still have the same activity as the proteins which comprise amino acid sequence 4 or/and sequence 5 or/and sequence 7.

Claim 8 (Withdrawn): The protein according to claim 7, wherein the said protein comprises sequence 4 amino acid sequence in the sequence listings.

Claim 9 (Withdrawn): The protein according to claim 7, wherein the said protein comprises sequence 5 amino acid sequence in the sequence listings.

Claim 10 (Withdrawn): The protein according to claim 7, wherein the said protein comprises sequence 7 amino acid sequence in the sequence listings.

Claim 11 (Withdrawn): The proteins according to claim 7 or 8 or 9 or 10, wherein the said proteins are related to liver cancer and some epithelium sourced cancers.

Claim 12 (Currently Amended): The An expression vectors of the human cancer-related isolated polynucleotide sequence gene according to claim 1.

Claim 13 (Currently Amended): The A transfected and mutated cell lines of the human cancer-related isolated polynucleotide sequence gene according to claim 1.

Claim 14 (Withdrawn): The primers for amplifying the gene according to claim 1.

Claim 15 (Canceled).

Claim 16 (Currently Amended): The A promoter of the human cancer-related isolated polynucleotide sequence according to claim 15 1, wherein the said promoter contains a nucleotide sequence of SEQ ID No: 8.

Claim 17 (Withdrawn): The reagents comprising various monoclonal and polyclonal antibodies as activity ingredients for the proteins according to claim 7.

Claim 18 (Withdrawn): An application of the human cancer-related gene according to claim 1, wherein the said gene is used in the preparation of reagents for cancer diagnosis.

Claim 19 (Withdrawn): The application according to claim 18, wherein the said cancers are liver cancer and some epithelium sourced cancers.

Claim 20 (Withdrawn): The application of the proteins according to claim 7 in the preparation of reagents for cancer diagnosis.

Claim 21 (Withdrawn): The proteins application according to claim 20, wherein the said cancers are liver cancer and some epithelium sourced cancers.